Last reviewed 2026-06-10 · How we verify

Spinal muscular atrophy with two copies of a healthy SMN2 gene — Treatment Landscape & Competitive Intelligence

Spinal muscular atrophy with two copies of a healthy SMN2 gene (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Spinal muscular atrophy with two copies of a healthy SMN2 gene, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer · 1 drug in Spinal muscular atrophy with two copies of a healthy SMN2 gene

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Spinal muscular atrophy with two copies of a healthy SMN2 gene:

• Spinal muscular atrophy with two copies of a healthy SMN2 gene treatment updates — RSS
• Spinal muscular atrophy with two copies of a healthy SMN2 gene treatment updates — Atom
• Spinal muscular atrophy with two copies of a healthy SMN2 gene treatment updates — JSON

Cite this brief

Drug Landscape (2026). Spinal muscular atrophy with two copies of a healthy SMN2 gene — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/spinal-muscular-atrophy-with-two-copies-of-a-healthy-smn2-gene. Accessed 2026-06-10.

Related

• Spinal muscular atrophy with two copies of a healthy SMN2 gene full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing